{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-080277","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2025-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.179440+00:00","generated_at":"2026-05-23T15:30:04.066683+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cue Biopharma inks collaboration with Boehringer Ingelheim for B cell depletion; $12M upfront","bullets":["Upfront payment of $12M; eligible for up to $345M in success-based research, development, and commercial milestones.","BI gets exclusive worldwide license to develop and commercialize CUE-501 and other B cell depletion molecules.","Cue prohibited from developing or commercializing any B cell depletion molecules during the 4-year research term.","BI will pay research support during research term; royalties on net sales subject to standard reductions.","Amendment with Einstein College of Medicine allows sublicense to BI and adjusts upstream payment obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-080277","json":"https://secwatch.observer/filing/0001193125-25-080277.json","markdown":"https://secwatch.observer/filing/0001193125-25-080277.md","text":"https://secwatch.observer/filing/0001193125-25-080277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525080277/0001193125-25-080277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525080277/d894534d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:30:04.066683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}